Events

Europe’s Green and Digital Transition: The Role of Technology Infrastructures in the new Pact for research and innovation
JUN
Thu
23
09:30 - 15:45

This was 3 years ago

Location

European Commission, Borschette Center, Brussels

Programmes
Research Infrastructures Digital, Industry & Space Climate, Energy, Mobility EIE Enhancing EU R&I

As part of the EU French Council Presidency, the European Commission, the French Alternative Energies and Atomic Energy Commission (CEA) and the European Association of Research and Technology Organisations (EARTO) have organised a high-level conference on "Europe’s Green and Digital Transition: The Role of Technology Infrastructures in the new Pact for Research and Innovation" which will take place on 23 June 2022 in Brussels.

Agenda and registration

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.